clinical trial · NCT07170800
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
WestVac Biopharma Co., Ltd.·phase2·recruiting·n = 60
TuberculosisMultidrug Resistant Pulmonary TuberculosisRifampicin-resistant TuberculosisJDB0131 100mgJDB0131 200mgDelamanid (D)
brief summary
This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.
started
Sep 19, 2025
primary completion
Feb 28, 2026
completion
Sep 4, 2026
last updated
Jan 30, 2026
official title
A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets With Delamanid in Patients With Rifampin-resistant Tuberculosis (JD-RISE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol